Literature DB >> 9758118

Sixteen-year coronary mortality in black and white men with diabetes screened for the Multiple Risk Factor Intervention Trial (MRFIT).

O Vaccaro1, J Stamler, J D Neaton.   

Abstract

BACKGROUND: Risk of coronary heart disease (CHD) mortality associated with diabetes is high and it is unclear to what extent the high mortality is due to modifiable risk factors. To explore this, mortality and predictors of CHD death are compared in a large cohort of black and white men with diabetes.
METHODS: In all, 610 black and 3997 white men who reported taking medication for diabetes and had no history of hospitalization for heart attack were screened by 22 centres for the Multiple Risk Factor Intervention Trial (MRFIT). At screening major risk factors for CHD were determined. Participants have been followed for an average of 16 years for vital status. Cause-specific mortality and predictors of CHD are compared for blacks and whites using proportional hazards regression.
RESULTS: Serum cholesterol and systolic blood pressure levels were similar in blacks and whites with diabetes, while diastolic blood pressure and percentage of smokers were higher in blacks (89 versus 86 mmHg and 47% versus 34%) and median income was lower. Coronary heart disease was the leading cause of death, accounting for 31% (68/221) and 44% (564/1293) of deaths among blacks and whites, respectively. Adjusted relative risks of CHD death and all cause mortality for blacks compared to whites were 0.71 (95% CI: 0.53-0.95) and 0.94 (95% CI: 0.75-1.11). Differences in reporting cause of death probably account for some of the black/white difference in CHD. High serum cholesterol, high blood pressure, and smoking increased risk of CHD death similarly in blacks and whites.
CONCLUSIONS: Serum cholesterol, blood pressure, and smoking are major influences on CHD mortality risk in both white and black men with diabetes. High prevalence of these factors indicates substantial potential for CHD prevention in both ethnic groups.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9758118     DOI: 10.1093/ije/27.4.636

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  20 in total

1.  Managing cardiovascular risk in patients with diabetes.

Authors:  L Rydén
Journal:  Heart       Date:  2000-09       Impact factor: 5.994

2.  Racial disparities in all-cause mortality among veterans with type 2 diabetes.

Authors:  Cheryl P Lynch; Mulugeta Gebregziabher; Carrae Echols; Gregory E Gilbert; Yumin Zhao; Leonard E Egede
Journal:  J Gen Intern Med       Date:  2010-06-08       Impact factor: 5.128

3.  Linda crane lecture 2008 "the challenge for the future: five steps to improve quality, incorporate prevention, maintain productivity, and have fun!".

Authors:  Hillegass Ellen
Journal:  Cardiopulm Phys Ther J       Date:  2008-06

4.  Impact of kidney function and urinary protein excretion on intima-media thickness in Japanese patients with type 2 diabetes.

Authors:  Yusuke Nakade; Tadashi Toyama; Kengo Furuichi; Shinji Kitajima; Yoshiyasu Miyajima; Mihiro Fukamachi; Akihiro Sagara; Yasuyuki Shinozaki; Akinori Hara; Miho Shimizu; Yasunori Iwata; Hiroyasu Oe; Mikio Nagahara; Hiroshi Horita; Yoshio Sakai; Shuichi Kaneko; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2015-02-03       Impact factor: 2.801

5.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017.

Authors:  Makoto Kinoshita; Koutaro Yokote; Hidenori Arai; Mami Iida; Yasushi Ishigaki; Shun Ishibashi; Seiji Umemoto; Genshi Egusa; Hirotoshi Ohmura; Tomonori Okamura; Shinji Kihara; Shinji Koba; Isao Saito; Tetsuo Shoji; Hiroyuki Daida; Kazuhisa Tsukamoto; Juno Deguchi; Seitaro Dohi; Kazushige Dobashi; Hirotoshi Hamaguchi; Masumi Hara; Takafumi Hiro; Sadatoshi Biro; Yoshio Fujioka; Chizuko Maruyama; Yoshihiro Miyamoto; Yoshitaka Murakami; Masayuki Yokode; Hiroshi Yoshida; Hiromi Rakugi; Akihiko Wakatsuki; Shizuya Yamashita
Journal:  J Atheroscler Thromb       Date:  2018-08-22       Impact factor: 4.928

6.  Does depression predict coronary heart disease and cerebrovascular disease equally well? The Health and Social Support Prospective Cohort Study.

Authors:  Hermann Nabi; Mika Kivimäki; Sakari Suominen; Markku Koskenvuo; Archana Singh-Manoux; Jussi Vahtera
Journal:  Int J Epidemiol       Date:  2010-04-01       Impact factor: 7.196

7.  Impact of hypertension stratified by diabetes on the lifetime risk of cardiovascular disease mortality in Japan: a pooled analysis of data from the Evidence for Cardiovascular Prevention from Observational Cohorts in Japan study.

Authors:  Yukiko Imai; Takumi Hirata; Shigeyuki Saitoh; Toshiharu Ninomiya; Yoshihiro Miyamoto; Hirofumi Ohnishi; Yoshitaka Murakami; Hiroyasu Iso; Sachiko Tanaka; Katsuyuki Miura; Akiko Tamakoshi; Michiko Yamada; Masahiko Kiyama; Hirotsugu Ueshima; Shizukiyo Ishikawa; Tomonori Okamura
Journal:  Hypertens Res       Date:  2020-07-03       Impact factor: 3.872

8.  Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial.

Authors:  Fumiyoshi Tsunoda; Ivor B Asztalos; Katalin V Horvath; George Steiner; Ernst J Schaefer; Bela F Asztalos
Journal:  Atherosclerosis       Date:  2016-01-22       Impact factor: 5.162

Review 9.  The economic consequences of diabetes and cardiovascular disease in the United States.

Authors:  Miguel A Ariza; Varsha G Vimalananda; James L Rosenzweig
Journal:  Rev Endocr Metab Disord       Date:  2010-03       Impact factor: 6.514

10.  Treatment intensification and risk factor control: toward more clinically relevant quality measures.

Authors:  Joseph V Selby; Connie S Uratsu; Bruce Fireman; Julie A Schmittdiel; Tiffany Peng; Nicolas Rodondi; Andrew J Karter; Eve A Kerr
Journal:  Med Care       Date:  2009-04       Impact factor: 2.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.